e8vk
Table of Contents



SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549


FORM 8-K

Current Report
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): March 8, 2004

ELI LILLY AND COMPANY

(Exact name of registrant as specified in its charter)
         
Indiana
(State or Other Jurisdiction
of Incorporation)
  001-06351
(Commission
File Number)
  35-0470950
(I.R.S. Employer
Identification No.)
         
Lilly Corporate Center
Indianapolis, Indiana

(Address of Principal
Executive Offices)
      46285
(Zip Code)

Registrant’s telephone number, including area code: (317) 276-2000

No Change

(Former name or former address, if changed since last report)



 


TABLE OF CONTENTS

Item 9. Regulation FD Disclosure
SIGNATURES
EXHIBIT INDEX
Financial Statements & Discussion and Analysis


Table of Contents

Item 9. Regulation FD Disclosure

Eli Lilly and Company (the “Company”) is furnishing to the Commission its 2003 audited consolidated financial statements and management’s discussion and analysis. The Company is participating in an investor conference at which the above financial information has been made available. The Company intends to file its Form 10-K for 2003 and mail to its shareholders the 2003 annual report to shareholders and proxy statement on or about March 12, 2004. The information is furnished as Exhibit 99.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

         
  ELI LILLY AND COMPANY
(Registrant)
 
 
  By:   /s/ Arnold C. Hanish  
    Name:   Arnold C. Hanish   
    Title:   Chief Accounting Officer   
 

Dated: March 9, 2004

 


Table of Contents

EXHIBIT INDEX

     
Exhibit Number
  Exhibit
99
  Audited Consolidated Financial Statements and Management’s Discussion and Analysis